HGCO19-COVID 19 Vaccine Candidate | UPSC

Spread the love

HGCO19-COVID 19 Vaccine Candidate _ UPSC

HGCO19-COVID 19 Vaccine Candidate | UPSC

      HEADLINES:

Department of Biotechnology provides seed funding for Gennova Biopharmaceuticals Ltd.’s novel mRNA based COVID 19 Vaccine candidate-HGCO19

      WHY IN NEWS:

HOT from PIB !

MINISTRY? :-Ministry of Science & Technology
SYLLABUS COVERED: GS 3:Health:Diseases

      LEARNING: 

For PRELIMS  you have to take notes on series of Vaccine Candidates in News . Start with this one and it is quite important . Funding , How it works and who are the vaccine developers can be asked in Prelims 2020 .

For MAINS nothing much here .

      ISSUE: 

The vaccine is likely to go to Clinical Trial before the year ends

COVID 19 VACCINE CANDIDATE-HGCO19

SUPPORTED BY

Vaccine Discovery Programme supported by the Department of Biotechnology, Govt. of India under Ind CEPI, implemented by BIRAC will soon move into clinical trials

DEVELOPERS

HDT Biotech Corporation, Seattle, USA, Gennova has developed an mRNA vaccine candidate (HGCO19)

FUNDING

  • DBT-BIRAC has facilitated the establishment of ‘first-of-its-kind’ mRNA-based vaccine manufacturing platform in India.
  • DBT has provided seed funding for the development of Gennova’s novel self-amplifying mRNA-based vaccine candidate for COVID19.

EXPECTED DELIVERY OF VACCINE

The company is working aggressively to ensure first human injection by the end of the year.

ABOUT HGCO19

  • The novel mRNA vaccine candidate, HGCO19, has all arsenal to guide the host cells to make the antigen -spike protein of the virus.
  • mRNA vaccine candidate is reported to interact with host cells receptor.

HGCO19 is supported by ‘lipid inorganic nanoparticle (LION)’ as a delivery vehicle.

  • The neutralizing antibody response of the vaccine in mice and non-human primates was comparable with the sera from the convalescent patients of COVID-19.

Advantages of HGCO19 are its mRNA platform design and delivery vehicle.

WORKING

  • HGCO19 uses a ‘self-replicating mRNA platform’ that ensures the low injectable dose(dose-sparing effect) and sustained antigen release for a longer duration.

Gennova’s m-RNA platform supported by DBT utilizes the advances in nucleic acid vaccine and delivery systems.

  • This vaccine candidate that makes use of nanotechnology has shown promise to be effective in animal models.

‘LION DELIVERY SYSTEM’

  • This has adjuvanting property
  • Enhanced storage stability
  • Reduced adverse effects
  • Improved permeability
  • Bio-available.

With demonstrated safety, immunogenicity, neutralization antibody activity in the rodent and non-human primate models.

ABOUT GENNOVA

  • Gennova Biopharmaceuticals Ltd is headquartered in Pune.
  • It is a biotechnology company dedicated to the research, development, production of biotherapeutics.

      IASbhai WINDUP: 

Diseases emanating from unknown and new pathogens require novel ideas for effective mitigation.

     SOURCES:THE HINDU & PIB | HGCO19-COVID 19 Vaccine Candidate | UPSC

DISCOVER MORE : GS-3

If you liked this article, then please subscribe to our YouTube Channel for Daily Current Affairs , Editorial Analysis & Answer writing video tutorials. You can also find us on Twitter and Facebook.


Spread the love

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

IASbhai will use the information you provide on this form to be in touch with you and to provide updates and marketing.